WeVote
Log In

Bill

Bill

S 4363

Engineering Biology Readiness Act

119th Congress Introduced by Ted Budd and 1 co-sponsor

Extends annual briefings on the National Biodefense Strategy and requires formal analysis with policy recommendations on risks from engineering biology to strengthen biodefense ove

Introduced in Senate
0
WeVote Research Nonpartisan
Bill Summary · S 4363

Summary of Bill: S. 4363 (118th/119th Congress window)

Title: A bill to extend the requirement for annual briefings on National Biodefense Strategy and to require analysis and recommendations relating to the risks of engineering biology, and for other purposes.

Note: Action history indicates introduction and referral to the Senate Committee on Homeland Security and Governmental Affairs, with co-sponsors Tim Kaine and Ted Budd.

1) Purpose and Intent

  • The core aim is to strengthen oversight and expert analysis related to national biodefense and the evolving field of engineering biology.
  • Specifically, the bill seeks to:
    • Extend the existing annual briefing requirement on the National Biodefense Strategy.
    • Require formal analysis and policy recommendations addressing risks associated with engineering biology.

2) Key Provisions and Changes

A. Annual Briefings on National Biodefense Strategy

  • Extends the statutory requirement for annual briefings to Congress regarding the National Biodefense Strategy.
  • Purpose of briefings: keep Congress informed about national biodefense posture, preparedness, strategy updates, and related actions by the executive branch.
  • Likely scope of briefing content (inferred based on typical biodefense briefs): current threat landscape, surveillance and detection capabilities, supply chain resilience, public health readiness, research and development priorities, interagency coordination, and funding requirements.

B. Analysis and Recommendations on Engineering Biology Risks

  • Directs or authorizes a formal analysis focused on the risks posed by engineering biology (e.g., synthetic biology, gene editing, bioengineering technologies) to national security, public health, and safety.
  • Expected outputs: assessment of potential misuse or accidental release risks, governance gaps, biosecurity/biocontainment concerns, and implications for industry, research institutions, and government oversight.
  • Requires recommendations to mitigate identified risks. Typical recommendations could cover: regulatory enhancements, biosafety and biosecurity standards, oversight mechanisms for research and dual-use technologies, workforce training, and international coordination.

C. “And for other purposes”

  • Placeholder language indicating the bill may include additional related provisions, such as:
    • Clarifications of authorities,
    • Reporting requirements,
    • Coordination with other biodefense or science policy initiatives,
    • Implementation timelines or pilot activities.

3) Who and What would be Affected

Affected Entities

  • Executive Branch agencies involved in biodefense, biosecurity, public health, and science policy (e.g., Homeland Security, Health and Human Services, Defense, and other relevant federal offices).
  • Congress, particularly the Senate committees with jurisdiction over homeland security, government operations, and related national security issues.
  • External stakeholders likely to be involved in briefings and analyses, including national laboratories, academic researchers, industry groups in biotechnology, and public health organizations.

Potential Impacts

  • Increased congressional oversight through more frequent and structured updates on biodefense strategy.
  • Enhanced risk assessment and governance framework for engineering biology technologies.
  • Possible development of new or updated policies, guidelines, or statutory safeguards based on the analysis and recommendations.

4) Procedural and Timeline Aspects

  • Introduced in the Senate and referred to the Committee on Homeland Security and Governmental Affairs on April 21, 2026.
  • Co-sponsors: Tim Kaine (D-VA) and Ted Budd (R-NC), indicating bipartisan support.
  • As of the action history, no further floor action or amendments are listed beyond referral. If advanced, the bill would typically undergo committee hearings, potential amendments, and then floor consideration in the Senate, followed by potential reconciliation with any companion House measure (if applicable).

5) Practical Implications and Considerations

  • The bill aims to institutionalize ongoing congressional visibility into biodefense planning amid rapid advances in biotechnology.
  • By requiring analysis of engineering biology risks, the bill acknowledges dual-use concerns and the need for proactive policy guidance without constraining innovation.
  • Implementation details (e.g., scope of the annual briefings, specific analysis methodologies, and timelines for producing recommendations) would be defined in the bill’s text and any accompanying committee reports or amendments.

If you’d like, I can tailor this summary to a specific audience (e.g., policymakers, educators, or biotech industry stakeholders) or provide a comparison with existing biodefense oversight provisions.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.